Jacobio Pharmaceuticals Reports Productive Interim

Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.

Jacobio Pharmaceuticals Group Co., Ltd. has reported a successful interim for the first half of 2024, with significant advancements in their drug pipeline including the development of their core products for various cancers. Notable achievements include the submission and priority review of their NSCLC treatment glecirasib, the progression of a Phase III trial for a combination therapy, and the receipt of orphan drug designation from the U.S. FDA for their pancreatic cancer treatment. Additionally, glecirasib has shown promising outcomes in various tumor types, underlining the company’s growing impact in the oncology sector.

For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.